INZ-701 is a fusion protein commercialized by Inozyme Pharma, with a leading Phase II program in Arterial Calcification. According to Globaldata, it is involved in 4 clinical trials, of which 3 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of INZ-701’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for INZ-701 is expected to reach an annual total of $11 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
INZ-701 is under development for the treatment of rare genetic diseases of ENPP1 deficiency (generalized arterial calcification infancy (GACI) and autosomal recessive hypophosphatemic rickets type II (ARHR2), rare genetic diseases of ABCC6 Deficiency (pseudoxanthoma elasticum or PXE), calciphylaxis and diseases of neointimal proliferation. It is administered through subcutaneous route.
Inozyme Pharma Overview
Isozyme Pharma Inc (Isozyme Pharma) is a biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Isozyme Pharma is headquartered in Boston, Massachusetts,the US.
The operating loss of the company was US$56.7 million in FY2021, compared to an operating loss of US$57 million in FY2020. The net loss of the company was US$56.6 million in FY2021, compared to a net loss of US$56.4 million in FY2020.
For a complete picture of INZ-701’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.